{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "At a Mother's Day gathering of his family last year, Andrew James Turner Jr. made an announcement: ''This is my last meal.'' Mr. Turner, a 73-year-old cancer patient in Charlotte, N.C., whose treatments brought him great discomfort and no improvement, had already wasted to 130 pounds from 210. ''He couldn't do anything that he enjoyed anymore,'' said his widow, Pat Turner. Mr. Turner told his family that he was having his feeding tube removed and that he would refuse further treatment and food. ''If you have any comments about that, I will listen to them,'' he told them, ''but this is my decision.''", "headline": {"main": "New Openness in Deciding When and How to Die", "kicker": "THE SCHIAVO CASE: THE DYING"}, "abstract": "Many Americans are quietly taking active role in their own deaths, some with help of their doctors and others through actions of their own that blur definition of suicide; experts say support for assisted suicide is likely to increase as baby boomers, long accustomed to making decisions that shape their lives, demand say over their deaths, as well; surveys suggest that more than half of Americans find physician-assisted suicide morally acceptable, although many people remain opposed, often on moral or religious grounds; Rabbi Leonard A Sharzer, doctor and bioethicist who opposes suicide on religious grounds, says news coverage of assisted suicide and controversial end-of-life issues, from Dr Jack Kevorkian and Schiavo to fight over Oregon's law, has made patients more comfortable talking about death; even in Oregon, where broadest range of choices is available, few take option of hastening death through suicide drugs; photos (M)", "print_page": "1", "word_count": 2012, "_id": "4fd25aea8eb7c8105d807a3b", "snippet": "Many Americans are taking an active role in their own deaths, some with the help of their doctors and others through actions of their own that blur the definition of suicide.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/03/21/health/21dying.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "SCHIAVO, MICHAEL"}, {"name": "persons", "value": "SCHINDLER, MARY"}, {"name": "persons", "value": "KEVORKIAN, JACK"}, {"name": "persons", "value": "SCHINDLER, BOB"}, {"name": "persons", "value": "SHARZER, LEONARD A"}, {"name": "persons", "value": "SCHIAVO, TERRI"}, {"name": "glocations", "value": "OREGON"}, {"name": "glocations", "value": "FLORIDA"}, {"name": "subject", "value": "PUBLIC OPINION"}, {"name": "subject", "value": "DEATH AND DYING"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "LIFE-SUSTAINING SUPPORT SYSTEMS, WITHDRAWAL OF"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}, {"name": "subject", "value": "NEWS AND NEWS MEDIA"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "John", "rank": 1, "lastname": "SCHWARTZ"}], "original": "By JOHN SCHWARTZ; James Estrin contributed reporting for this article"}, "document_type": "article", "pub_date": "2005-03-21T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "When Amylin Pharmaceuticals won federal approval on Wednesday for its first drug, executives celebrated by jumping into the reflecting pond at the company's office complex in San Diego. Some also called to thank a little-known software entrepreneur back east in Washington who had helped make it all possible. The entrepreneur, Allen Andersson, invested in Amylin in early 1999, when the company was facing collapse because the drug, a diabetes treatment called Symlin, failed to demonstrate statistically meaningful effects in two clinical trials.", "headline": {"main": "Investing for a Profit and a Daughter's Health"}, "abstract": "Article on Allen Andersson, entrepreneur who invested $34 million in Amylin Pharmaceuticals in early 1999 when company faced collapse because clinical trials of diabetes treatment called Symlin were faltering; Andersson thought drug would help his daughter Rachel, who has diabetes; his Amylin holdings, now that federal government has approved drug, are worth $200 million; photo (M)", "print_page": "1", "word_count": 1136, "_id": "4fd257218eb7c8105d8018e8", "snippet": "Amylin Pharmaceuticals, which won federal approval for its first drug on Wednesday, was saved from collapse by the father of a girl with diabetes.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/03/19/business/19drug.html", "multimedia": [{"url": "images/2005/03/19/business/drug.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2005/03/19/business/drug.75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "persons", "value": "ANDERSSON, ALLEN"}, {"name": "organizations", "value": "AMYLIN PHARMACEUTICALS INC"}, {"name": "organizations", "value": "AMYLIN PHARMACEUTICALS INCORPORATED"}, {"name": "subject", "value": "DIABETES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "SYMLIN (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2005-03-19T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Genentech Inc.'s cancer drug Avastin prolonged the lives of patients with advanced lung cancer in a clinical trial, a result that sent the company's shares soaring and could pave the way for wider use of what is widely considered the company's most promising product. In the trial, sponsored by the National Cancer Institute, patients who received Avastin along with standard chemotherapy drugs had a median survival of 12.5 months, compared with 10.2 months for those receiving only the chemotherapy.", "headline": {"main": "Genentech Drug Shows Effect on a 2nd Cancer"}, "abstract": "Genentech Inc's cancer drug Avastin prolonged lives of patients with advanced lung cancer in clinical trial sponsored by National Cancer Institute, result that sends company's shares soaring and could pave way for wider use of what is widely considered company's most promising product; patients who received Avastin along with standard chemotherapy drug had median survival of 12.5 months, compared with 10.2 months for those receiving only chemotherapy; Genentech's shares rise $10.92, or 25 percent, to close at $55; photo (M)", "print_page": "1", "word_count": 728, "_id": "4fd247818eb7c8105d7e2e29", "snippet": "Genentech Inc.'s cancer drug Avastin prolonged the lives of patients with advanced lung cancer in a clinical trial, a result that sent the company's shares soaring.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/03/15/business/15drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "GENENTECH INC"}, {"name": "organizations", "value": "GENENTECH INCORPORATED"}, {"name": "organizations", "value": "NATIONAL CANCER INSTITUTE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "CHEMOTHERAPY"}, {"name": "subject", "value": "LUNGS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "AVASTIN (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2005-03-15T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 3, "offset": 0, "time": 59}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}